Contraindications for Naltrexone in Alcohol Use Disorder
Naltrexone is absolutely contraindicated in patients currently using opioids, those dependent on opioids (including methadone or buprenorphine maintenance), patients in acute opioid withdrawal, anyone who fails a naloxone challenge test or has positive urine opioid screening, and those with known hypersensitivity to naltrexone. 1
Absolute Contraindications
The FDA drug label clearly defines the following as absolute contraindications 1:
- Current opioid use or dependence: This includes patients on opioid analgesics, methadone maintenance, or partial agonists like buprenorphine
- Acute opioid withdrawal: Naltrexone will precipitate or severely exacerbate withdrawal symptoms
- Failed naloxone challenge test or positive urine opioid screen: Indicates ongoing opioid presence in the system
- Known hypersensitivity to naltrexone or its components
Critical Pitfall to Avoid
The most dangerous error is initiating naltrexone in patients who are not completely opioid-free. This can precipitate severe, potentially life-threatening opioid withdrawal 1. Patients must be opioid-free for 7-10 days before starting naltrexone 1.
Hepatotoxicity Concerns: The Evidence Has Changed
Contrary to historical concerns, naltrexone is NOT contraindicated in patients with alcohol-associated liver disease (ALD), including those with cirrhosis. This represents a major shift in clinical practice 2, 3, 4.
What the Evidence Shows:
- Hepatotoxicity only occurs at doses 5-6 times higher (up to 300 mg/day) than the standard 50 mg/day dose used for AUD 1, 5
- At the recommended 50 mg daily dose, naltrexone has not been associated with clinically significant liver injury 2
- Recent studies demonstrate safety even in patients with severe alcohol-associated cirrhosis 3, 4
- Injectable extended-release naltrexone (XR-NTX) avoids first-pass hepatic metabolism and shows no hepatotoxicity or hepatic decompensation in advanced ALD 6
Liver Disease Considerations:
Naltrexone can be used in compensated and decompensated cirrhosis 2, 3. The AASLD guideline notes hepatotoxicity concerns but does not list liver disease as a contraindication 2. The only uncertain scenario is severe acute hepatitis or acute-on-chronic liver failure, where data are lacking, though the benefits of reducing alcohol consumption may outweigh theoretical risks 3.
Relative Contraindications and Precautions
While not absolute contraindications, exercise caution in:
- Acute hepatitis: Unknown safety profile, though not formally contraindicated 3
- Patients requiring opioid analgesia: Must discontinue naltrexone before opioid use for pain management or surgery 1
Practical Implementation
Before prescribing naltrexone:
- Screen for opioid use: Urine drug screen and detailed medication history
- Verify opioid-free status: 7-10 day minimum washout period 1
- Consider naloxone challenge test if opioid use is uncertain 1
- Baseline liver function tests: For monitoring, not as a contraindication 2
- Patient education: Warn about inability to achieve opioid effects if they use opioids while on naltrexone
The outdated practice of avoiding naltrexone in liver disease should be abandoned 4. This misconception has led to significant undertreatment of AUD, with fewer than 3% of eligible patients receiving naltrexone in Australia 3, despite its proven efficacy and safety profile.